Penumbra (PEN) Projected to Announce Earnings on Wednesday

Penumbra (NYSE:PEN) is anticipated to issue its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of $1.20 per share and revenue of $401.41 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Penumbra (NYSE:PEN) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.88 earnings per share for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.28). The firm had revenue of $390.05 million during the quarter, compared to analyst estimates of $389.64 million. The business’s revenue was up 14.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.86 EPS. On average, analysts expect Penumbra to post $4.96 EPS for the current fiscal year and $6.12 EPS for the next fiscal year.

Penumbra Trading Down 2.1%

PEN stock opened at $317.35 on Wednesday. The firm has a 50 day moving average of $320.93 and a 200 day moving average of $327.37. Penumbra has a 52 week low of $221.26 and a 52 week high of $362.41.

Analyst Upgrades and Downgrades

PEN has been the subject of a number of research analyst reports. Evercore restated an “outperform” rating and issued a $320.00 target price on shares of Penumbra in a research note on Monday, July 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of Penumbra in a research note on Thursday, October 15th. Finally, Zacks Research raised Penumbra from a “strong sell” rating to a “hold” rating in a report on Monday, August 24th. Three equities research analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company’s stock. According to data from MarketBeat, Penumbra presently has a consensus rating of “Hold” and an average price target of $367.07.

About Penumbra

Penumbra, Inc is a medical device company that develops, manufactures and markets products used to treat patients with vascular conditions. Its technologies are primarily designed for minimally invasive procedures in the neurovascular and peripheral vascular markets, including the treatment of ischemic stroke, brain aneurysms and other vascular disorders.

The company’s product portfolio includes aspiration and mechanical thrombectomy systems for removing blood clots, embolization devices for blocking abnormal blood flow, and access and delivery products used during endovascular procedures.